Jennifer Ruth Brown MD PhD

PubMed

• Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia.
  James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel Sungchul Choi, Stacey M Fernandes
  Blood Advances. 2025-04-03
• Investigating the influence of germlinevariants in chronic lymphocytic leukemia on cancer vulnerability.
  Roberta S Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva
  Haematologica. 2025-04-01
• Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia.
  Yanping Yin, Haifeng Xu, Liye He, Jennifer R Brown, Anthony R Mato
  Clinical Cancer Research. 2025-03-14

Abstracts/Posters

• Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Future of Chronic Lymphocytic Leukemia (CLL) Therapy 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• 17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma® 
  Physicians' Education Resource, LLC, New York, New York - 2/15/2013
• Join now to see all